Aquestive Therapeutics, Inc. (AQST) Spending and interest coverage
- R&D / revenue · 12 months: Value 29.38%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 17.32%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 29.38% | Research and development expense / revenue. Period ending 2026-06-30. $15.89M ÷ $54.09M × 100 ≈ 29.38% |
| Stock-based compensation / revenue · 12 months | 17.32% | Share-based compensation / revenue. Period ending 2026-06-30. $9.37M ÷ $54.09M × 100 ≈ 17.32% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.89M USD | Research and Development Expense |
| Revenue | 54.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.37M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -52.74M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.89M | $54.09M | $9.37M | $-52.74M | (m) | 29.38% | 17.32% | (m) | (m) |
| 2026-03-31 | $16.04M | $50.27M | $8.36M | $-55.89M | (m) | 31.90% | 16.62% | (m) | (m) |
| 2025-12-31 | $17.19M | $44.55M | $7.62M | $-71.05M | (m) | 38.59% | 17.12% | (m) | (m) |
| 2025-09-30 | $18.91M | $43.40M | $8.65M | $-55.79M | (m) | 43.58% | 19.93% | (m) | (m) |
| 2025-06-30 | $19.65M | $44.13M | $7.45M | $-52.60M | (m) | 44.53% | 16.88% | (m) | (m) |
| 2025-03-31 | $19.71M | $54.23M | $7.11M | $-41.18M | (m) | 36.34% | 13.10% | (m) | (m) |
| 2024-12-31 | $20.28M | $57.56M | $7.10M | $-30.77M | (m) | 35.23% | 12.33% | (m) | (m) |
| 2024-09-30 | $18.25M | $58.90M | $5.64M | $-21.10M | (m) | 30.99% | 9.57% | (m) | (m) |
| 2024-06-30 | $16.18M | $58.36M | $4.83M | $-15.19M | $9.09M | 27.72% | 8.28% | -1.67× | Reported |
| 2024-03-31 | $15.49M | $51.50M | $3.92M | $-19.45M | $7.69M | 30.07% | 7.62% | -2.53× | Reported |
| 2023-12-31 | $13.10M | $50.58M | $2.69M | $-15.10M | $6.34M | 25.91% | 5.32% | -2.38× | Reported |
| 2023-09-30 | $14.49M | $48.06M | $2.46M | $-21.90M | $5.71M | 30.16% | 5.12% | -3.83× | Reported |
| 2023-06-30 | $14.53M | $46.52M | $2.22M | $-28.38M | $6.11M | 31.23% | 4.78% | -4.65× | Reported |
| 2023-03-31 | $16.25M | $46.54M | $3.81M | $-36.93M | $6.37M | 34.92% | 8.19% | -5.80× | Reported |
| 2022-12-31 | $17.48M | $47.68M | $4.38M | $-42.07M | $6.55M | 36.66% | 9.19% | -6.42× | Reported |
| 2022-09-30 | $17.60M | $48.08M | $5.36M | $-43.02M | $6.65M | 36.61% | 11.14% | -6.47× | Reported |
| 2022-06-30 | $19.10M | $49.90M | $6.72M | $-42.14M | $7.78M | 38.27% | 13.47% | -5.41× | Reported |
| 2022-03-31 | $18.16M | $51.98M | $6.22M | $-35.89M | $8.91M | 34.94% | 11.98% | -4.03× | Reported |
| 2021-12-31 | $17.05M | $50.83M | $6.82M | $-34.68M | $10.05M | 33.54% | 13.41% | -3.45× | Reported |
| 2021-09-30 | $17.07M | $46.90M | $6.66M | $-38.66M | $11.07M | 36.40% | 14.19% | -3.49× | Reported |
| 2021-06-30 | $19.61M | $41.88M | $6.18M | $-44.47M | $11.06M | 46.82% | 14.77% | -4.02× | Reported |
| 2021-03-31 | $19.19M | $48.21M | $6.23M | $-37.56M | $11.05M | 39.81% | 12.92% | -3.40× | Reported |
| 2020-12-31 | $19.89M | $45.85M | $6.58M | $-42.89M | $11.06M | 43.37% | 14.35% | -3.88× | Reported |
| 2020-09-30 | $18.52M | $55.12M | $6.92M | $-37.15M | $11.10M | 33.60% | 12.56% | -3.35× | Reported |
| 2020-06-30 | $16.32M | $59.28M | $7.37M | $-34.37M | $10.97M | 27.53% | 12.43% | -3.13× | Reported |
| 2020-03-31 | $20.63M | $48.73M | $7.41M | $-53.45M | $10.16M | 42.32% | 15.21% | -5.26× | Reported |
| 2019-12-31 | $20.57M | $52.61M | $7.07M | $-52.67M | $9.32M | 39.11% | 13.44% | -5.65× | Reported |
| 2019-09-30 | $23.20M | $53.01M | $6.60M | $-55.12M | $8.42M | 43.76% | 12.45% | -6.55× | Reported |
| 2019-06-30 | $22.67M | $53.86M | $5.96M | $-53.32M | $7.70M | 42.09% | 11.07% | -6.93× | Reported |
| 2019-03-31 | $22.51M | $56.66M | $31.46M | $-67.31M | $7.71M | 39.73% | 55.52% | -8.73× | Reported |
| 2018-12-31 | $23.11M | $67.43M | $29.94M | $-48.93M | $7.71M | 34.28% | 44.40% | -6.35× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $73.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $22.13M | $66.92M | $0.00 | $-113.00K | $7.71M | 33.07% | 0.00% | -0.01× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |